On the other hand, when TS is overexpressed, CRC patients usually do not respond to 5-FU-based schemes, such as the FOLFOX regimen (5-FU, oxaliplatin, and leucovorin) [34]. This evidence concerns the gene TYMS and colorectal carcinoma.